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INTRODUCTION
Fibromyalgia (FM) is a common, chronic widespread pain disorder that is estimated to impact 0.5% to 7% of the general population worldwide (Balon and Wise, 2015) . The epidemiology of FM in Latvia has not been studied in detail. Host individuals diagnosed in clinics are young or middle aged; however, population surveys suggest that frequency of disease increases with age as well as symptom severity and worsening of life quality (Ballantyne et al., 2010; Branco et al., 2010; Jiao et al., 2014; Balon and Wise, 2015) . Females suffer from FM eight times more frequently than males (Albin et al., 2008) .
The term fibromyalgia appeared relatively recently, in 1976. Diagnosis is clinical and is based on the 1990 American College of Rheumatology (ACR) diagnostic criteria. According to these criteria, FM diagnosis may be stated if the patient has chronic widespread pain and 11 or more positive of a possible 18 tender points on physical examination, fatigue, sleep disorders, headaches, memory or concentration problems, mood disturbances, and stiffness.
In 2010, ACR FM diagnostic criteria were supplemented with new details (Hakim et al., 2010; Wolfe et al., 2011) that include the estimation of the widespread pain index (WPI) and the symptoms of severity (SS) score scale. The SS scale score is the sum of the severity of three symptoms (fatigue, waking unrefreshed, cognitive symptoms) plus the extent of somatic symptoms in general.
The aetiology and pathogenesis of FM are still unknown. This disease is probably of multi-factorial nature, since many patients have onset of the clinical phenotype of FM PROCEEDINGS OF THE LATVIAN ACADEMY OF SCIENCES. Section B, Vol. 70 (2016 ), No. 4 (703), pp. 205-210. DOI: 10.1515 /prolas-2016 following a specific trigger. There are many open questions with few or controversial answers. Such triggers can include various viral infections, such as hepatitis C (Kozanoglu et al., 2003; Mohammad et al., 2012; Rogal et al., 2015) , parvovirus B19 (Cassisi et al., 2011) , HIV (Kole et al., 2013; Wiffen et al., 2013; Fox and Walker-Bone, 2015) , and Epstein-Barr virus (Buchwald et al., 1987) . 55% of patients identify a "flu-like" or viral infection as a precursor to the onset of symptoms, but the role of viral infection in FM development has not been estimated.
One of the major theories is that cytokines may have a role in both the aetiology of the FM and in the intensity of core symptoms (Menzies and Lion, 2010) . Goldberg (1989) suggests that the viruses might directly invade central nervous system or are capable of activating cytokines which may in turn cause severe myalgia, fatigue, and neurocognitive disturbances.
According to the current state of knowledge the origin of the pain in FM and variety of FM symptoms are triggered by peripheral as well as central mechanisms (Sprott, 2011; Clauw et al., 2011) .
Up to date, there are no data on the role of HHV-6 and HHV-7 infection in the FM development. Human herpesvirus-6 (HHV-6) and -7 (HHV-7) belong to the Herpesviridae family, Betaherpesvirinae subfamily, Roseolovirus genus (Berneman et al., 1992) and are ubiquitous (more than 90% of adults have antibodies to the viruses) immunomodulating, and potentially pathogenic to the nervous system. In 2012, the International Committee on Taxonomy of Viruses re-classified HHV-6 as separate viruses HHV-6A and HHV-6B based on biocharacteristics regarding cell tropism and pathological implications (Ablashi et al., 2014) . After primary infection, the viruses establish a state of life-long subclinical persistence or latency in CNS (Yoshikawa and Asano, 2000) and can be reactivated in cases of immunosuppression. HHV-6A, HHV-6B and HHV-7 DNA are often found in brain tissue from healthy individuals (without pathological changes in the brain) (Chan et al., 2001; Yao et al., 2010) .
HHV-6 infection has been associated with neurologic pathologies such as multiple sclerosis (Ablashi et al., 2000; Chapenko et al., 2003; Nora-Krukle et al., 2011) , which is associated with inflammation, mesial temporal lobe epilepsy in the absence of inflammation in brain tissue (Donati et al., 2003; Fotheringham et al., 2007; Niehusmann et al., 2010) , myalgic encephalomyelitis/chronic fatigue syndrome (Ablashi et al., 2000; Chapenko et al., 2006; Bansal et al., 2012; Chapenko et al., 2012) and with different neurological complications after allogeneic hematopoietic stem cell transplantation (Bhanushali et al., 2013) and solid organ transplantations (Chapenko et al., 2009; Massih and Razonable, 2009 ). The association of HHV-7 infection with these disorders is not sufficiently studied.
HHV-6 and HHV-7 infection profoundly modifies the profile of cytokine and chemokine production, which in turn may significantly affect the generation and functionality of effective immune responses (Lusso et al., 2006) . Lusso (2006) and Atedzoe et al. (1999) have shown that both of the viruses increase the production of inflammatory cytokines.
The aim of this study was to: 1) examine the presence of HHV-6 and/or HHV-7 genomic sequences in whole peripheral blood and cell free plasma DNA samples from patients with FM and practically healthy persons (control group); 2) determine HHV-6 variant-specificity in whole peripheral blood DNA; 3) compare HHV-6 and HHV-7 load in peripheral blood samples from the FM patients and control persons; 4) compare pro-inflammatory cytokine TNF-a plasma level in patients with FM and control group individuals.
MATERIALS AND METHODS
The study was performed during 2013-2015. Clinical and virological (including serology and molecular biology) features were examined in the 41 patients with clinical diagnose of primary FM and 50 practically healthy persons. The primary FM diagnosis was established by a neurologist or algologist in the out-patients' clinic of Pauls Stradiòð Clinical University Hospital. None of the 41 patients with primary diagnosed FM were hospitalised in the Neurology and Neurosurgery Hospital. According to case and drug history, 10 of the 41 patients had not received prior medical treatment; none of the patients had received steroids or statins, but pain relief medication only.
Diagnosis was setup based on ACR 2010 diagnostic criteria for the FM (Widespread pain index (WPI) is equal or more than 7, symptom severity scale score (SS) -equal or more than 5, duration of symptoms at least three months, and the patients do not have a disorder that would otherwise explain the pain). In our FM patients group the mean WPI was 12.7 ± 3.24 (minimal score 4 and maximal score 18), and mean SS scale score -8.1 ± 1.4 (minimal score 6 and maximal score 11). Mean duration of symptoms was 7.9 ± 6.2 years. Exclusion criteria were previously known polyneuropathy, cervical radiculopathy clinical symptoms, diabetes mellitus, rheumatoid arthritis, liver diseases, myalgic encephalomyelitis/chronic fatigue syndrome, and myocardial infarction.
Of 41 individuals with FM, 40 were females and one was male (mean age 51, range: 24-71) and from 50 control group individuals, 40 were females and 10 were males (mean age 48, range: 35-78). Peripheral blood samples from the patients with FM were received from the Neurology and Neurosurgery Department, Rîga Stradiòð University.
The study was approved by the Ethics Committee of Rîga Stradiòð University, and all of the participants gave informed consent before the examination.
HHV-6 and HHV-7 serology. Testing for antibodies against HHV-6 and HHV-7 in cell free blood plasma samples was carried out using HHV-6 IgG ELISA kits (Panbio, Sinnamon Park, QLD, Australia) and HHV-7 IgG ELISA kits (ABI, Columbia MD, ASV) in accordance with the manufacturer's recommendations.
Nested polymerase chain reaction (nPCR).
The technique of nPCR was used for the detection of viral genomic sequences in DNA isolated from whole peripheral blood (WPB) and cell free blood plasma. Total DNA was isolated from WPB using standard phenol-chloroform extraction. The QIAamp DNA Blood Mini Kit was used to extract DNA from plasma. To assure the quality of the DNA, a b-globin PCR was performed. PCR amplification for the viruses was carried out in the presence of 1 µg WPB DNA and 10 µl plasma DNA (corresponding to 100 µl plasma). HHV-6 and HHV-7 DNA were detected in accordance with Secchiero et al. (1995) and Berneman et al. (1992) , respectively. Positive controls (HHV-6 and HHV-7 genomic DNA; ABI, Columbia, MD, USA) and negative controls (DNA obtained from practically healthy HHV-6 and HHV-7 negative donors and reaction without template DNA), as well as water controls were included in each experiment.
Restriction endonuclease analysis.
Restriction endonuclease analysis was carried out using enzyme HindIII (Thermo Scientific, USA) which cleaves HHV-6B 163bp amplimer into two fragments: 66 and 97 bp and does not cleave HHV-6A amplimer ( Secchiero et al., 1995) .
Quantitative real-time polymerase chain reaction. HHV-6 load was detected in all positive (according to nPCR data) for viral DNA WPB samples from the patients with FM and controls group individuals using a HHV-6 Real-TM Quant kit (Sacace, Biotechnologies, Italy) and Applied Biosystems 7500 Real-time PCR System (Applied Biosystems, USA), according to the manufacturer's recommendations. The test sensitivity corresponded to five copies of the HHV-6 DNA per 10 5 cells. HHV-7 load was detected in all positive (according to nPCR data) for viral DNA samples from the patients with FM and controls group individuals using Quantification of Human Herpes Virus 7 genomes Major Capsid Protein (U57) (PrimerDesign TM Ltd, genesig detection kits). The test sensitivity is not indicated.
Assay for cytokine determinations.
A TNF-a ELISA kit (Biorbyt) was used for TNF-a detection in plasma samples from the FM patients with persistent infection in latent phase and active phase, and without viral infection. The sensitivity of the ELISA assay was < 1 pg/ml. All samples were tested in duplicate.
Statistical analysis. Statistical differences in the detection frequency of HHV-6 and/or HHV-7 genomic sequences in the DNA samples from WPB of the individuals with FM as well as the control group persons were assessed with the Fisher's exact test. The plasma cytokine level (TNF-a) was expressed as mean ± SD. SPSS software was used to assess the continuous variable values of cytokine level with a value of p < 0.05 considered as significant. HHV-6 and/or HHV-7 genomic sequences in patients with fibromyalgia. Roseolovirus genomic sequences were detected in 80% (33/41) versus 62.0% (31/50) in control group individuals (p = 0.067). The detection frequency of single HHV-6, single HHV-7 and concurrent HHV-6+ HHV-7 genomic sequences in the FM patients and control group individuals are summarized in Table 1 .
RESULTS

Seroepidemiology. Specific anti-HHV-
No difference in the frequency of single HHV-6 and single HHV-7 infection between FM patients and control group individuals was detected (p = 0.204). However, a significantly higher detection rate of concurrent (HHV-6+HHV-7) infection markers was revealed in FM patients in comparison with control group individuals (15/41, 36.6% vs 2/50, 4.0%, respectively; p = 0.00008).
Plasma viremia (marker of active viral infection) was revealed only in patients with FM (6/33, 18.2%). As shown in the Table 1 , HHV-6 genomic sequence in plasma DNAs upon single HHV-6 persistent infection was detected in two of three patients, simultaneous activation of both viruses upon concurrent persistent infection in two of 15, and HHV-7 genomic sequences in two out of 15 FM patients with single HHV-7 persistent infection.
HHV-6 and HHV-7 load in whole peripheral blood. Mean HHV-6 and HHV-7 load levels were higher in FM patients compared to the healthy persons. The mean HHV-6 load in WPB of FM patients with persistent infection in latent phase was 752. TNF-a level. To investigate the relationship between the reactivation of HHV-6 and/or HHV-7 and changes in plasma cytokine level, the level of pro-inflammatory cytokine TNF-a was measured in FM patients with persistent infection in latent phase (27/41), FM patients with active viral infection (6/41), and without viral infection (8/41). The TNF-a level was significantly higher in patients with active viral infection (39.33 ± 35.50 pg/ml, p = 0.018) and in those with persistent infection in latent phase (19.75 ± 8.84 pg/ml, p = 0.044) than in the patients without viral infection (5.33 ± 1.53 pg/ml).
Determination of HHV-6 variant-specificity. HHV-6A was identified in two and HHV-6B in 16 of 18 FM patients positive for HHV-6 infection. HHV-6B was identified in all control individuals.
DISCUSSION
Fibromyalgia (FM) is a chronic disorder that is part of a spectrum of syndromes manifested by diffuse musculoskeletal pain and additional somatic symptoms like fatigue, sleep, emotional disturbance, depression, cognitive symptoms, gastrointestinal symptoms, and headache. The disorder can have a devastating effect on peoples' lives and also imposes large economic burdens on society.
Although inflammatory, infectious, and autoimmune disorders have all been ascribed to be aetiological events in the development of FM, there is very little data to support such a thesis (Borchers and Gershwin, 2015) .
At present, clinical diagnostic criteria for FM has been elaborated (Wolfe et al., 2010) ; however, the aetiology and pathophysiology of the disease remains unclear (Albin et al., 2008) .
Up to date, no data exist on the role of HHV-6 and HHV-7 infection in FM development, although HHV-6 and HHV-7 are ubiquitous viruses with immunomodulating properties and are potential pathogens to the nervous system (Lusso, 2006) .
We investigated the detection frequency of single HHV-6, single HHV-7 and concurrent HHV-6+HHV-7 genomic sequences in DNA samples isolated from WPB and cell-free blood plasma from patients with clinically diagnosed FM and control group subjects (Table 1) . Although the results of our study show no difference in the detection frequency of single HHV-6 and single HHV-7 infection, the rate of concurrent HHV-6+HHV-7 infection is significantly higher in patients with FM than in healthy individuals (p = 0.00008). Active viral infection (plasma viremia) was detected only in FM patients (18.2%).
Increase of mean HHV-6 and HHV-7 loads in WPB of FM patients with persistent infection in latent phase as well as with active infection, in comparison with control subjects, was found.
We found limited empirical evidence to support the association of increased pro-inflammatory cytokine levels with FM development (Menzies and Lyon, 2010) . Our results showed that significantly higher TNF-a level occurred in FM patients with active viral infection as well as in patients with persistent infection in latent phase, in comparison with control group individuals. Taking into account the immunomodulating properties of these viruses, quantitative and qualitative changes on system levels of cytokines in the patients with FM cannot be excluded.
At present, the question of potential interaction between HHV-6 and HHV-7 in cases of concurrent infection is not clear. Significantly frequent detection of concurrent infection and simultaneous activation of both viruses only in FM patients allow to suggest the potential interaction between these viruses as well as in development of FM. Our results are in accordance with previous in vitro (Katsafanas et al., 1996; Tanaka-Taya et al., 2000) and in vivo (Boutolleau et al., 2003; Hall et al., 2006) studies.
More frequent detection of HHV-6B in FM patients and healthy individuals indicates that either HHV-6A occurs infrequently in these individuals or that there is a difference in HHV-6A and HHV-6B geographical distribution and the HHV-6B in our area is predominant (Boutolleau et al., 2006; Bates et al., 2009 ).
CONCLUSION
Significantly higher detection frequency of concurrent HHV-6 and HHV-7 infection, simultaneous HHV-6 and HHV-7 activation, higher HHV-6 and HHV-7 load, as well as increased expression level of TNF-a in patients with FM, in comparison with control group individuals, indicate a potential association of roseolovirus infection with primary fibromyalgia
